GSK Strengthens Nucala's COPD Case With Phase III Success

GSK recently unveiled the topline results of its Phase III MATINEE trial, which evaluated the efficacy of the injectable antibody Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD). The trial demonstrated that Nucala significantly reduced the annual rate of moderate to severe exacerbations in patients with COPD, compared to a placebo. This outcome marks a noteworthy step in GSK's attempt to expand Nucala’s indications to include COPD, a condition for which it is not currently approved.

Despite GSK's announcement, the company did not disclose specific numerical data, only stating that the reduction in exacerbations was both "statistically significant and clinically meaningful." In terms of safety, the adverse effects observed with Nucala in the MATINEE trial were consistent with its known safety profile. The pharmaceutical company plans to present comprehensive results at an upcoming scientific congress and share the data with health regulatory authorities.

Nucala is a monoclonal antibody administered via subcutaneous injection and targets the IL-5 cytokine, which is integral to the growth, activity, and survival of eosinophils. By inhibiting IL-5, Nucala mitigates the inflammatory responses central to various respiratory conditions. The FDA initially approved Nucala in November 2015 for severe asthma in patients aged 12 years and older. Since then, its approved uses have expanded to include chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES).

The MATINEE trial was a comprehensive late-stage, double-blind, randomized, and placebo-controlled study involving over 800 patients. Participants received either Nucala or a placebo in addition to their optimized maintenance therapies for a period that ranged from at least 52 weeks to a maximum of 104 weeks.

GSK's endeavor to validate Nucala for COPD also includes earlier trials, METREX and METREO, which were concluded in 2017. The recent MATINEE results are part of a broader effort to solidify Nucala's position in the COPD treatment landscape.

This latest update from GSK coincides with a critical period in the COPD treatment field, as Sanofi and Regeneron are on the verge of potentially securing approval for their antibody Dupixent later this month. Supported by data from their Phase III BOREAS and NOTUS trials, Dupixent has shown promise in reducing acute exacerbations and enhancing lung function in COPD patients. While the FDA initially set a target action date in June following the acceptance of a supplemental Biologics License Application in February 2024, the review was postponed when the agency requested additional efficacy data. The new PDUFA date is now set for September 27.

In addition, Verona's Ohtuvayre received approval in late June 2024, marking the introduction of a novel mechanism of action for COPD treatment in over a decade. The drug showed significant improvements in lung function, as measured by forced expiratory volume, in the late-stage ENHANCE-1 and ENHANCE-2 studies. It also demonstrated efficacy in reducing exacerbations and delaying the onset of the first exacerbation.

As the COPD treatment market evolves with these advancements, Nucala’s successful expansion into this area would place it alongside key competitors like Dupixent and Ohtuvayre, potentially offering new therapeutic options for patients suffering from this chronic respiratory condition.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!